Xian-De Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7007777/publications.pdf

Version: 2024-02-01

840776 1058476 5,346 13 11 14 citations h-index g-index papers 15 15 15 14672 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1017-1029.	3.4	159
3	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 2018, 361, 290-295.	12.6	134
4	PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nature Communications, 2020, 11, 2135.	12.8	114
5	miR-200c inhibits TGF- \hat{l}^2 -induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer. Cancer Gene Therapy, 2018, 25, 68-76.	4.6	70
6	Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clinical Cancer Research, 2020, 26, 4970-4982.	7.0	45
7	Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival. Oncotarget, 2016, 7, 6255-6265.	1.8	40
8	Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein. Cancer Research, 2014, 74, 3127-3136.	0.9	20
9	HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Research, 2017, 77, 5313-5326.	0.9	19
10	The impact of FGFR1 and FRS2 \hat{l}_{\pm} expression on sorafenib treatment in metastatic renal cell carcinoma. BMC Cancer, 2015, 15, 304.	2.6	16
11	Autophagy degrades hypoxia inducible factors. Molecular and Cellular Oncology, 2016, 3, e1104428.	0.7	12
12	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers, 2021, 13, 1475.	3.7	10
13	Dysregulation of HIF2α and autophagy in renal cell carcinoma. Molecular and Cellular Oncology, 2015, 2, e965643.	0.7	3